Synergistic activity of S63845 and parthenolide to overcome acquired resistance to MEK1/2 inhibitor in melanoma cells: Mechanisms and therapeutic potential
Open Access
- 26 May 2025
- journal article
- Published by Elsevier in Biomedicine & Pharmacotherapy
- Vol. 188
Abstract
No abstract availableFunding Information
- Medical University of Lodz (503/1\u2013156\u201301/503\u201311\u2013001)
This publication has 72 references indexed in Scilit:
- Evaluation of BH3 mimetics as a combination therapy with irradiation in head and neck squamous cell carcinomaBiomedicine & Pharmacotherapy, 2024
- Green nanotech paradigm for enhancing sesquiterpene lactone therapeutics in cancerBiomedicine & Pharmacotherapy, 2024
- Costunolide and parthenolide: Novel blood-brain barrier permeable sesquiterpene lactones to improve barrier tightnessBiomedicine & Pharmacotherapy, 2023
- Exploring and validating the metastasis mechanism of pathenolide interfering with cutaneous melanoma through ER stress‐dependent apoptosis based on the network pharmacologyPhytochemical Analysis, 2022
- Engineered nanoparticles as emerging gene/drug delivery systems targeting the nuclear factor-κB protein and related signaling pathways in cancerBiomedicine & Pharmacotherapy, 2022
- Global Burden of Cutaneous Melanoma in 2020 and Projections to 2040JAMA Dermatology, 2022
- Nanomedicines: Redefining traditional medicineBiomedicine & Pharmacotherapy, 2021
- Application of sesquiterpene lactone: A new promising way for cancer therapy based on anticancer activityBiomedicine & Pharmacotherapy, 2018
- MITF in melanoma: mechanisms behind its expression and activityCellular and Molecular Life Sciences, 2014
- Parthenolide induces caspase‐independent and AIF‐mediated cell death in human osteosarcoma and melanoma cellsJournal of Cellular Physiology, 2012